Financial Ratios Xunfei Healthcare Technology Co., Ltd.
Equities
2506
CNE100006MP5
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 79.65 HKD | +3.51% |
|
+1.85% | +0.70% |
| 03-30 | Xunfei Healthcare's Loss Narrows 51% in 2025; Shares Slip 5% | MT |
| 03-27 | Xunfei Healthcare Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
Profitability | |||||
Return on Assets | - | -17.67 | -12.72 | -6.32 | -3.6 |
Return on Total Capital | - | -36.96 | -27.74 | -11.18 | -6.41 |
Return On Equity % | - | -46.52 | -32.48 | -17.91 | -6.8 |
Return on Common Equity | - | -49.34 | -34.49 | -18.43 | -7.06 |
Margin Analysis | |||||
Gross Profit Margin % | 50.4 | 48.88 | 56.58 | 55.05 | 50.45 |
SG&A Margin | 42.96 | 57.06 | 49.56 | 39.24 | 33.73 |
EBITDA Margin % | -27.56 | -53.13 | -36.78 | -18.55 | -10.36 |
EBITA Margin % | -28.32 | -53.96 | -38.05 | -19.72 | -11.34 |
EBIT Margin % | -35.5 | -61.23 | -41.49 | -22.91 | -13.85 |
Income From Continuing Operations Margin % | -24 | -44.21 | -27.73 | -18.75 | -7.19 |
Net Income Margin % | -22.47 | -40.14 | -26.04 | -18.07 | -7.08 |
Net Avail. For Common Margin % | -22.47 | -40.14 | -26.04 | -18.07 | -7.08 |
Normalized Net Income Margin | -17.07 | -28.63 | -19.42 | -13.99 | -6.46 |
Levered Free Cash Flow Margin | - | 8.02 | -62.69 | -16.98 | -49.05 |
Unlevered Free Cash Flow Margin | - | 8.09 | -62.55 | -16.45 | -48.27 |
Asset Turnover | |||||
Asset Turnover | - | 0.46 | 0.49 | 0.44 | 0.42 |
Fixed Assets Turnover | - | 41.77 | 41.33 | 39.4 | 38.88 |
Receivables Turnover (Average Receivables) | - | 2 | 1.4 | 1.17 | 1.01 |
Inventory Turnover (Average Inventory) | - | 6.09 | 4.01 | 3.74 | 3.87 |
Short Term Liquidity | |||||
Current Ratio | 1.49 | 1.08 | 1.27 | 1.68 | 1.41 |
Quick Ratio | 1.4 | 0.97 | 1.13 | 1.53 | 1.07 |
Operating Cash Flow to Current Liabilities | -0.11 | -0.19 | -0.47 | -0.13 | -0.04 |
Days Sales Outstanding (Average Receivables) | - | 182.81 | 261.36 | 313.68 | 359.71 |
Days Outstanding Inventory (Average Inventory) | - | 59.97 | 91.01 | 97.84 | 94.31 |
Average Days Payable Outstanding | - | 229.46 | 335.25 | 346.57 | 363.04 |
Cash Conversion Cycle (Average Days) | - | 13.32 | 17.12 | 64.95 | 90.99 |
Long Term Solvency | |||||
Total Debt/Equity | 16.01 | 0.18 | 16.29 | 25.75 | 29.86 |
Total Debt / Total Capital | 13.8 | 0.18 | 14.01 | 20.48 | 22.99 |
LT Debt/Equity | 0.14 | - | 0.09 | 7.04 | 14.59 |
Long-Term Debt / Total Capital | 0.12 | - | 0.08 | 5.6 | 11.24 |
Total Liabilities / Total Assets | 50.97 | 61.17 | 55.57 | 52.78 | 59.01 |
EBIT / Interest Expense | -45.67 | -489.72 | -190.55 | -27.39 | -11.08 |
EBITDA / Interest Expense | -34.96 | -421.94 | -167.66 | -21.91 | -8.02 |
(EBITDA - Capex) / Interest Expense | -37.05 | -432.08 | -176.6 | -23.22 | -11.72 |
Total Debt / EBITDA | -0.79 | -0 | -0.44 | -1.89 | -3.08 |
Net Debt / EBITDA | 3.5 | 0.99 | 0.38 | 3.14 | -1.74 |
Total Debt / (EBITDA - Capex) | -0.74 | -0 | -0.42 | -1.78 | -2.11 |
Net Debt / (EBITDA - Capex) | 3.31 | 0.97 | 0.36 | 2.96 | -1.19 |
Growth Over Prior Year | |||||
Total Revenues, 1 Yr. Growth % | - | 26.69 | 17.86 | 31.98 | 24.66 |
Gross Profit, 1 Yr. Growth % | - | 22.87 | 36.41 | 28.42 | 14.24 |
EBITDA, 1 Yr. Growth % | - | 144.23 | -18.4 | -33.42 | -30.4 |
EBITA, 1 Yr. Growth % | - | 141.41 | -16.89 | -31.6 | -28.29 |
EBIT, 1 Yr. Growth % | - | 118.54 | -20.14 | -27.11 | -24.64 |
Earnings From Cont. Operations, 1 Yr. Growth % | - | 133.33 | -26.07 | -10.76 | -52.22 |
Net Income, 1 Yr. Growth % | - | 126.27 | -23.53 | -8.45 | -51.14 |
Normalized Net Income, 1 Yr. Growth % | - | 112.48 | -20.06 | -4.91 | -42.48 |
Diluted EPS Before Extra, 1 Yr. Growth % | - | 90.32 | -23.61 | -10.66 | -53.98 |
Accounts Receivable, 1 Yr. Growth % | - | 58.8 | 74.61 | 48.43 | 39.92 |
Inventory, 1 Yr. Growth % | - | 44.87 | 56.82 | 39.88 | 27.79 |
Net Property, Plant and Equip., 1 Yr. Growth % | - | 0.39 | 37.79 | 38.88 | 17.33 |
Total Assets, 1 Yr. Growth % | - | 1.56 | 20.21 | 68.87 | 10.64 |
Tangible Book Value, 1 Yr. Growth % | - | -25.99 | 102.74 | 141.83 | -10.1 |
Common Equity, 1 Yr. Growth % | - | -20 | 46.17 | 88.44 | -4.61 |
Cash From Operations, 1 Yr. Growth % | - | 116.27 | 175.87 | -57.33 | -67.96 |
Capital Expenditures, 1 Yr. Growth % | - | -1.32 | 80.96 | -25.38 | 423.85 |
Levered Free Cash Flow, 1 Yr. Growth % | - | - | -1.02K | -64.26 | 260.22 |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | - | -1.01K | -65.28 | 265.75 |
Compound Annual Growth Rate Over Two Years | |||||
Total Revenues, 2 Yr. CAGR % | - | - | 22.19 | 24.72 | 28.27 |
Gross Profit, 2 Yr. CAGR % | - | - | 29.46 | 32.36 | 21.13 |
EBITDA, 2 Yr. CAGR % | - | - | 41.17 | -26.29 | -31.93 |
EBITA, 2 Yr. CAGR % | - | - | 41.65 | -24.6 | -29.96 |
EBIT, 2 Yr. CAGR % | - | - | 32.11 | -23.7 | -25.89 |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | - | 31.34 | -18.77 | -34.7 |
Net Income, 2 Yr. CAGR % | - | - | 31.54 | -16.33 | -33.12 |
Normalized Net Income, 2 Yr. CAGR % | - | - | 30.33 | -12.81 | -26.04 |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | 20.58 | -17.39 | -35.88 |
Accounts Receivable, 2 Yr. CAGR % | - | - | 66.52 | 60.99 | 44.11 |
Inventory, 2 Yr. CAGR % | - | - | 50.73 | 48.11 | 33.7 |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | - | 17.61 | 38.34 | 27.65 |
Total Assets, 2 Yr. CAGR % | - | - | 10.49 | 42.47 | 36.69 |
Tangible Book Value, 2 Yr. CAGR % | - | - | 22.49 | 121.42 | 47.44 |
Common Equity, 2 Yr. CAGR % | - | - | 8.13 | 65.96 | 34.07 |
Cash From Operations, 2 Yr. CAGR % | - | - | 144.26 | 8.5 | -63.02 |
Capital Expenditures, 2 Yr. CAGR % | - | - | 33.63 | 16.2 | 97.71 |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 81.5 | 13.47 |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 77.82 | 12.68 |
Compound Annual Growth Rate Over Three Years | |||||
Total Revenues, 3 Yr. CAGR % | - | - | - | 25.37 | 24.7 |
Gross Profit, 3 Yr. CAGR % | - | - | - | 29.12 | 26.02 |
EBITDA, 3 Yr. CAGR % | - | - | - | 9.88 | -27.69 |
EBITA, 3 Yr. CAGR % | - | - | - | 11.13 | -25.85 |
EBIT, 3 Yr. CAGR % | - | - | - | 8.35 | -24.02 |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | - | 15.47 | -31.94 |
Net Income, 3 Yr. CAGR % | - | - | - | 16.57 | -30.06 |
Normalized Net Income, 3 Yr. CAGR % | - | - | - | 17.33 | -24.1 |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | - | 9.11 | -32.02 |
Accounts Receivable, 3 Yr. CAGR % | - | - | - | 60.26 | 53.64 |
Inventory, 3 Yr. CAGR % | - | - | - | 47.02 | 41 |
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | - | 24.31 | 30.95 |
Total Assets, 3 Yr. CAGR % | - | - | - | 27.27 | 30.96 |
Tangible Book Value, 3 Yr. CAGR % | - | - | - | 53.67 | 63.96 |
Common Equity, 3 Yr. CAGR % | - | - | - | 30.13 | 37.99 |
Cash From Operations, 3 Yr. CAGR % | - | - | - | 36.55 | -27.75 |
Capital Expenditures, 3 Yr. CAGR % | - | - | - | 10.04 | 91.96 |
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | - | 128.09 |
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | - | 126.14 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















